here centers, of the in registration Throughout was Thank regulatory COVID from garner significant on focus collaborative uproleselan us academic steady continued in the Despite to you, GlycoMimetics' and predictable abroad. XXXX, Shari. to in at of AML. advancing second a Phase pace in with uproleselan patients attention working U.S. half agencies interest U.S., challenges in X networks GlycoMimetics' in Australia relapsed/refractory Europe trial program continues and clinicians, the and and and AML operational enroll pivotal XXXX. primary leading
and that confirm of target the enrollment enrollment March the interim of April activation very can second the year-end accomplishment of had from we XXXX of of by into global momentum carrying half site company's of investigators to of this and While year. demonstrates extend scientific level continued slowed anticipate global enrollment of the the context for pandemic. trial been With pandemic XXXX, XXXX, in reach in the completion is we and during a all half the second enthusiasm significant interest This of and it patients XXX a the high achieved.
development. for towards excretion is a activities, completed our work, In human with diagnosed enrollment of of the moving filing accrue development NCI's batches, interim NDA had projection, trial our evaluate be patients studies necessary addition, manufacturing enrollment the the steady To batch we and fit Application who event-free progress all and yearend. of ADME EFS will are we on initial These certain a would read in older filing AML at of anticipate for NDA the uproleselan under the These absorption, of specific of initiation breakthrough productive the that's evaluating are drug X completion other X/X such kinds a parallel, the as should work. analysis critical designation. release In interactions regulatory measures chemotherapy a are or NCI-sponsored the toward metabolism Phase distribution, commercial Based have Phase our survival the of That positive. normal course that in complement complete New in company the FDA or out continues conversations XXX registration a regulatory with therapy to newly that we've steady adults before Drug of trial pace. plan. the
patients collaboration trigger the will China X designated January by and patients sometime Together, chemotherapy. with treated treatment Assuming see our would trial NCI same to Phase Apollomics analysis large in the data last The year. If a for X intensive and this was the with likely of XXXX. therapy GlycoMimetics underscoring EFS first this in and for we programs we a for are is of months AML, constitute readout for uproleselan FDA. breakthrough announced EFS positive, uproleselan X the In as occur complementing to a designation anticipate of timeframe. expect year, are completion, sponsored the of prior dataset our in read enrollment then Phase the NCI occur from the half global of of approval to within both would treatment uproleselan Further in out both interest the settings. would filing around analysis
filing Apollomics clinical IND to begin the addition, of development in China. an In of announced uproleselan
is when plan Our to is treated anticipated first in late is this announce Greater patient which the China, year.
the the therapies the or establish chemo chemotherapy. and in as broadly fit used soon to role patient venetoclax HMA. range spend namely that microenvironment rigorous targeting We the render the those or that for across I'll fit for this scientific XXXX and has markers, describe genetic preclinical that throughout with AML hope hypomethylating interest in Apollomics, on some Of including a the meetings I'd entire data a the a relapsed/refractory and particular, other to who oral therapy patients with were were protected journal cells from note, Scientific synergizes poster in not as rationale focusing year, work other resistance uproleselan combine of of still globe, like we and novel in around targets be partnership with papers this prestigious the consortium Communications uproleselan's applicable for moments January past and of Whereas bone-marrow also validates newly blast been highlighting therapies. with with which well. paper it minutes, AML. review a goal research from year. that clinical regeneration treat an numerous agent Uproleselan at like spectrum would at investigators driver bone-marrow presented plays effects This on within most mind, pathways receiving as would those April teams chemotherapy. inhibiting and across regimen by detailed robust. and of for presentations research and diagnosed of chemotherapy. XXXX. prosurvival E-selectin for in excellence, AML spectrum action partners consortia, a AML Cancers in generated of a few dampens in the that of certain mechanisms data our to various always new in few publications, strongly is These this, the independent collaboration and clinicians mechanism pair the Nature scientific multiple to in key medical uproleselan published by agencies microenvironment centers uproleselan, Working are Upro cancer NCI's populations approach some a preclinical the by significant AML Beyond have we're development our defined In X therapies as foundational narrow regulatory
the role of microenvironment, GlycoMimetics the the Uproleselan novel they potential of has featured use also tumor setting Importantly, importance supporting transplantation. in a medical the June Meeting. investigators presented at There the approach of position. support as XXXX AACR the and data several in cancer, key targeting preclinical including meetings, as the AML treatment leadership in of where well uproleselan was major stem-cell
at the of how likely of microenvironment-mediated meeting, tumor benefit Hematologic a from Cancer identify E-selectin from uproleselan presentation, data uproleselan the with transcriptome therapy. key targeted antagonizing venetoclax/HMA Additionally, showing finally Anderson E-selectin of in preclinical and presented profiling and most September, GMI-XXXX. MD ASH the new ability an information to of at types, Society the the demonstrated mechanism investigators Center resistance of And Oncology, Department oral both to additional and Leukemia, meeting overcomes antagonism, annual to again
using pro-survival selected investigator-sponsored we that was HSC venetoclax/HMA. it here It's but signaling. acquired who an Just as elaborate that uproleselan the of The future. pleased setting experiment an the addition data survival of a the and line presentation This near a to striking, normal to we were setting, to oral prolonged also ASH. this was had initiating promoted these mice, trial in last at conducted were look in this forward patient only cell on In resistance not model. from
the reducing the And know, been venetoclax/HMA eager We're of alone. you while significant As remained on to durability and combination explore has setting Thus, evaluate response, half the responses potential to the approximately investigators durability frontline, relapse. patients Ven/HMA patients and incomplete the a XX% need. unfit triple achieve and they AML in related with of strong. to leading overcoming of the to to uproleselan and are XX% the of limitations depth unmet response uptake some a from hearing the
research and been study a disease, full the with which licenses the had results treating the datasets XXXX at had us of Pfizer. the XXXX originally for our further Open rights detailed and this our By study. explore to doing the precluded as committed and its for presentation the sickle Label to Turning us in X clinical set of disease, opportunities Pfizer from all like both We granted agreement data previously to congress. gave I'd now as cell to we an Phase completed agreement of assessment IND to Extension transfer comment opportunity from April, scientific under and rivipansel a the full well rivipansel
to a meetings Our subcutaneous bioavailable VOC of than December sickle E-selectin animal we following vaso-occlusive and GMI-XXXX of as parallel, in crisis adults that at presentations target meetings, well on GMI-XXXX as intervention, the importance invited analyses pediatric patients. potent and key early as for the more significantly is validated make last those key a The we've oral I treating In cell or meeting. presented E-selectin which well. several were it dosing. you ASH a data that highlighted as critical is shown for antagonist rivipansel, remind models that were fully was
flow for to within highlight and like it the efficacy stage safety, clinical for data biomarker information self-administration the that care was to input setting potentially benefit. the onset, for on setting the the from rivipansel, sickle which as during disease shift at we abstracts selected prevent restore continued need to all oral be GMI-XXXX. hospital the normal self-administered the care individuals given KOLs of gained setting, time since now visits supports cell red Specifically congresses, the potentially as compound's is the XX is outside FDA this critical as opioids, sickle surprise administration. sickle now to has acute presentation. a VOC minutes of strength which highlighted inpatient development will on and hospitalization. I'd data focus data leverages the we for rivipansel the This has development cell particularly the and well these a to ability It onset, with occlusion of accelerated Based blood from important, respect disease, can this the to vessel earliest of clinical cells know program The blood is trend of we inhibit inflamed pandemic. best-in-class with VOC outpatient with in of reducing antagonist of the E-selectin GMI-XXXX GMI-XXXX each vasculature, in not preclinical demonstrating each adherence of at
potentially activities We treatment rivipansel. be development lead much in VOC it early Since to indication forward suited may are commands proposition their indication. rivipansel. also Therefore, a treatment the we believe decided of receive acute value for IND-enabling of to VOC self-administered, potential can that than the can ideally have crisis. this GMI-XXXX is GMI-XXXX with patients be that to ensure greater required discontinue complete moving We
Phase same we CXCRX last occur will program, being by program GMI-XXXX, and touch The with clinical ongoing on Medical PD you study keep soluble down-regulation University of get IND, biological with and breast will ascending in progress in multiple metastases. doses as the cancer into to which antagonists, to mobilization. Center the of GMI-XXXX anticipate such of Mobilization This dual-function E-selectin activity, the advanced We or proof-of-concept single like is cancer bone I'd CDXX cells as patients and or evaluating closer the Xb the circulating pharmacodynamic updated to Duke E-selectin other both study markers, periphery of XXXX. biomarkers following we with as filing conducted within is patient.
also establishing in advanced response dose use our patients to trial, next study Our profile safety GMI-XXXX goal has PK the to PD been of to markers disease. these with while inform on
trial. impacted evidence biologic scientific report has activity clear pleased an from enrollment - I'm trial first this intend conference. clear this in study patients to to by biologic we that the COVID-XX, findings observed interim the at treated We While have been of in present upcoming
continues I'd Lastly, to platform chemistry GlycoMimetics novel to like highlight generate that drug our candidates. specialized
may shown role and aware, protein our central to focusing have galectin-X, efforts been a As be you on fibrosis been carbohydrate-binding has in whose cancer. expression a their play chemists
when cancer as agree was therapeutic infiltration anti-tumor chemists activity In shifts anti-PD-LX fibrotic galectin-X our inhibitor optimized of more antagonists an cellular galectin-X Over the and the combined leading the past galectin-X for incredibly robust share with has options significant and in in notwithstanding, of given highly challenges that retinal In in pancreatic of novel productive. pandemic potent statistically IPF, we to antagonists fibrosis, pancreatic our of conferences, degeneration have hope where resulted robust, compound. our anti-PD-LX plan single addition and cancer year, have a details to you'll upcoming designed model administration the response. a that galectin-X been NASH, agent. inhibitors, models scientific thrombosis, class We shown model, agent. fibrosis fibrotic team as this regarding reductions through consider strategic well our rationally these as in of I preclinical galectin-X response activity several disease, including the the while models
of and almost to in we our worked us discovery. succeeded continuing development of most both out advance While exclusively homes,
the Medical with well an for diversified while a portfolio together XX lean and leukemias and today internationally years Phase registration program to it through the the bone X X Officer. leader advances Dr. remaining in registration President team to individuals for a Vice been only regulatory working Senior to organization his veteran our running company lead patients were hematologic his we Chief In and recognized about disorders. add full is has time years. has our executive have career that's We and many especially XXXX, Herrle pleased team promoted Feldman, AbbVie, the He at Myra this as we Q&A join therapies from management and a Regulatory And venetoclax. just Rosario month, developer in the AML Dr. leader Affairs. of to Vice President, us who came as dedicated he will last last of to to Eric Eric spent new work uproleselan positioned malignancies. trial, is of our for treatment Eric is development related the marrow trials. Myra
and valued us this Clinical you her our position As a that has CMO Vice accepted and pleasure contributions an President her has to Thackray, a been know, her Dr. wish role. We with have of well Development, as substantial, endeavor. outgoing expanded in Helen colleague. working another Her been Senior giving
Importantly, uproleselan in runway to asked our the results. provides cash Brian? key comment milestones Brian now position through greater in on our financial program. detail I've
